Nextcure, Inc. (NXTC) Stock Price & Analysis
Nextcure, Inc. (NXTC) fell 16.49% to USD 2.33 as of June 10, 2026 at 04:07 UTC, according to Nexqual real-time market data.
NXTC last closed at USD 2.79; the session ranged USD 2.28–2.9 on volume of 133,249 shares. Market capitalization is $8.42M, with a 52-week range of USD 2.28–15.74 (NMS). Source: Nexqual, June 10, 2026 at 04:07 UTC.
Key Statistics (as of June 10, 2026 at 04:07 UTC)
| Price | USD 2.33 |
|---|---|
| Change | ▼ 16.49% (down) |
| Previous Close | USD 2.79 |
| Open | USD 2.85 |
| Day Range | USD 2.28 – 2.9 |
| 52-Week Range | USD 2.28 – 15.74 |
| Volume | 133,249 shares |
| Market Cap | $8.42M |
| Exchange | NMS |
Technical Analysis (NXTC)
Nexqual's technical model rates NXTC "SELL" based on 2 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 04:07 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 21.67 (oversold) |
| vs SMA50 | Below (USD 9.2) |
| MACD | -1.94 (negative) |
Analyst Ratings (NXTC)
Wall Street analysts rate NXTC "Strong Buy" based on 3 analysts, with a mean price target of USD 19.33 (range USD 15–25), per Nexqual as of June 10, 2026 at 04:07 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 19.33 |
| High Target | USD 25 |
| Low Target | USD 15 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (NXTC)
| EPS Estimate | USD -1.87 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.87 vs est -2.03 ▲ beat |
| 2025-12-31 | USD -0.81 vs est -2.29 ▲ beat |
| 2025-09-30 | USD -3.22 vs est -3.98 ▲ beat |
| 2025-06-30 | USD -11.29 vs est -4.62 ▼ miss |
Source: Nexqual, June 10, 2026 at 04:07 UTC.
Financials & Fundamentals (NXTC)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -132.41% |
| Debt / Equity | 14.52 |
| Current Ratio | 4.61 |
| Total Cash | $29.74M |
| Total Debt | $3.88M |
| Free Cash Flow | $-27.14M |
Source: Nexqual, June 10, 2026 at 04:07 UTC.
Financial Health Score (NXTC)
Nexqual rates Nextcure, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 04:07 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $30M cash vs $4M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$50M |
| Efficiency | Critical — ROE -132%, ROA -66.7% |
Ownership (NXTC)
| Insider Ownership | +14.84% |
|---|---|
| Institutional Ownership | +62.54% |
| Shares Outstanding | 3.61M |
| Float | 2.28M |
| Short % of Float | +1.90% |
Source: Nexqual, June 10, 2026 at 04:07 UTC.
Leadership (NXTC)
Nextcure, Inc. is led by Michael S. Richman MSBA (age 64), Co-Founder, CEO, President & Director, per Nexqual as of June 10, 2026 at 04:07 UTC.
| Co-Founder, CEO, President & Director | Michael S. Richman MSBA (age 64) |
|---|---|
| Chief Operating Officer | Timothy Mayer (age 60) |
| Co-Founder & Chairman of Scientific Advisory Board | Lieping Chen (age 68) |
| Chief Financial Officer | Steven P. Cobourn (age 62) |
| Senior Vice President of Development & Manufacturing | Sourav Kundu (age 64) |
Major Backers & Investors (NXTC)
Notable institutional backers of Nextcure, Inc. include Squadron Capital Management LLC, Affinity Asset Advisors, Llc, Ikarian Capital, LLC, according to Nexqual as of June 10, 2026 at 04:07 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Squadron Capital Management LLC | 7.34% |
| Affinity Asset Advisors, Llc | 6.69% |
| Ikarian Capital, LLC | 6.6% |
| Sofinnova Investments, Inc. | 6.16% |
| SilverArc Capital Management, LLC | 4.87% |
| Pfizer Inc | 4.25% |
| Opaleye Management Inc. | 3.91% |
| AWM Investment Company, Inc. | 3.25% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.88% |
Source: Nexqual, June 10, 2026 at 04:07 UTC.
From Nextcure, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Payload – A proprietary novel TOPO1 inhibitor known as CPT116, with a drug-to-antibody ratio (DAR) of 8, has demonstrated high systemic clearance for reduced toxicity due to its hydrophilic properties. 7 Table of Contents In December 2024, Zaiming received FDA clearance for its IND for a Phase 1 clinical trial to treat multiple cancers.
- We seek to protect our proprietary technology and processes, in part, by confidentiality and invention assignment agreements with our employees, consultants, scientific advisors and other contractors.
- Review and Approval for Licensing Biologics in the United States In the United States, the FDA regulates our current product candidates as biological products, or biologics, under the Federal Food, Drug, and Cosmetic Act, or "FDCA", the Public Health Service Act and associated implementing regulations.
- The FDA may also require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess the drug's safety after approval.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ASMB | Assembly Biosciences, Inc. | USD 22.72 | ▼ 0.79% |
| PASG | Passage Bio, Inc. | USD 5.57 | ▼ 0.89% |
| CTMX | CytomX Therapeutics, Inc. | USD 2.98 | ▼ 0.67% |
| MGTX | MeiraGTx Holdings plc | USD 9.21 | ▲ 2.33% |
| STOK | Stoke Therapeutics, Inc. | USD 29.37 | ▼ 2.13% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:07 UTC. This page is informational and not investment advice.